Last reviewed 2026-05-31 · How we verify

HX9428 tablet

Fujian Haixi Pharmaceuticals Co., Ltd. · Phase 1 active Small molecule ✓ Verified May 2026

HX9428 tablet is a Small molecule drug developed by Fujian Haixi Pharmaceuticals Co., Ltd.. It is currently in Phase 1 development.

HX9428 is a small molecule glucocorticoid receptor agonist tablet being studied for the treatment of Wet Age-related Macular Degeneration (AMD). The tablet is being evaluated in a multicenter, open-label, Phase I/II clinical trial (NCT07185841) for its safety and efficacy in subjects with wAMD.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	HX9428 tablet
Sponsor	Fujian Haixi Pharmaceuticals Co., Ltd.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety and Efficacy of Oral HX9428 Tablets in Subjects With Wet Age-related Macular Degeneration (wAMD) (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

HX9428 tablet CI brief — competitive landscape report
HX9428 tablet updates RSS · CI watch RSS
Fujian Haixi Pharmaceuticals Co., Ltd. portfolio CI

Frequently asked questions about HX9428 tablet

What is HX9428 tablet?

HX9428 tablet is a Small molecule drug developed by Fujian Haixi Pharmaceuticals Co., Ltd..

Who makes HX9428 tablet?

HX9428 tablet is developed by Fujian Haixi Pharmaceuticals Co., Ltd. (see full Fujian Haixi Pharmaceuticals Co., Ltd. pipeline at /company/fujian-haixi-pharmaceuticals-co-ltd).

What development phase is HX9428 tablet in?

HX9428 tablet is in Phase 1.

Manufacturer: Fujian Haixi Pharmaceuticals Co., Ltd. — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing